Zoe Waibler
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Zoe Waibler has a total of 144 co-authors. Here are the top co-authors by number of shared publications:
Martina Anzaghe
Division of Immunology, Paul-Ehrlich-Institut, Langen, Germany
8 shared publicationsStefanie Kronhart
Paul‐Ehrlich‐Institut VPr1—Immunological and Biopharmaceutical Research Langen Germany
8 shared publicationsLilija Miller
Division of Immunology, Paul-Ehrlich-Institut, Langen, Germany
7 shared publications- Patricia Gogesch
Division of Immunology, Paul-Ehrlich-Institut, Langen, Germany
7 shared publications Patricia Gogesch
Paul‐Ehrlich‐Institut VPr1—Immunological and Biopharmaceutical Research Langen Germany
5 shared publications- Samira Ortega Iannazzo
Paul-Ehrlich-Institut, Division of Immunology, Langen, Germany
5 shared publications
Latest Publications
- Open Access
- 10 August 2026
- Published by Wiley in Cell Biochemistry and Function
- Vol. 44 (8) , e70279
Mycoplasma Contamination Alters the Expression Profile of Pro‐Inflammatory Cytokines by Human Innate Immune Cells
The impact of Mycoplasma contaminations on in vitro test systems has been extensively discussed and in vitro studies have demonstrated various effects on the physiology of the contaminated cell line. Thus far, little is known about the effect of biologically active substances, such as viruses produced in contaminated cell lines on primary immune cells. Therefore, the aim of the present study was to pinpoint the impact of Mycoplasma contamination on human innate immune cells. To address this, myeloid dendritic cells (mDC) and two types of macrophages (type M1 and M2) were in vitro differentiated from healthy donors and treated with different volumes of cell‐culture supernatant from Mycoplasma ‐contaminated VeroE6 cells (SN(M)). Depending on the cell type, Mycoplasma contamination mediated a decrease in viability and the pre‐activation of the immune cells. Surprisingly, small amounts of SN(M) were sufficient to induce the secretion of massive amounts of pro‐inflammatory interleukin (IL)−6 and, to a lesser extent, tumor necrosis factor (TNF)‐α and interleukin (IL)−10. Moreover, SN(M) co‐stimulation of cells treated with a variety of toll‐like receptor (TLR) ligands and different RNA‐encoded viruses differentially altered their activation status, depending on the analyzed markers, cell types, and stimuli. Furthermore, SN(M) co‐treatment strongly influenced the induced cytokine profile of mDC as well as M1 and M2 macrophages upon treatment with various stimuli, especially upon viral infection. In line with this, a batch of SARS‐CoV‐2 produced in Mycoplasma ‐contaminated VeroE6 cells induced high levels of IL‐6 and TNF‐α while treatment with the non‐contaminated virus stock did not result in expression of cytokines. Our data indicate that Mycoplasma contamination has a major impact on the experimental outcome of infection experiments using human immune cells and therefore can result in misinterpretation of experimental data.
- 10 August 2026
- Published by Wiley in Cell Biochemistry and Function
- Vol. 44 (8) , e70279
Open AccessMycoplasma Contamination Alters the Expression Profile of Pro‐Inflammatory Cytokines by Human Innate Immune Cells
The impact of Mycoplasma contaminations on in vitro test systems has been extensively discussed and in vitro studies have demonstrated various effects on the physiology of the contaminated cell line. Thus far, little is known about the effect of biologically active substances, such as viruses produced in contaminated cell lines on primary immune cells. Therefore, the aim of the present study was to pinpoint the impact of Mycoplasma contamination on human innate immune cells. To address this, myeloid dendritic cells (mDC) and two types of macrophages (type M1 and M2) were in vitro differentiated from healthy donors and treated with different volumes of cell‐culture supernatant from Mycoplasma ‐contaminated VeroE6 cells (SN(M)). Depending on the cell type, Mycoplasma contamination mediated a decrease in viability and the pre‐activation of the immune cells. Surprisingly, small amounts of SN(M) were sufficient to induce the secretion of massive amounts of pro‐inflammatory interleukin (IL)−6 and, to a lesser extent, tumor necrosis factor (TNF)‐α and interleukin (IL)−10. Moreover, SN(M) co‐stimulation of cells treated with a variety of toll‐like receptor (TLR) ligands and different RNA‐encoded viruses differentially altered their activation status, depending on the analyzed markers, cell types, and stimuli. Furthermore, SN(M) co‐treatment strongly influenced the induced cytokine profile of mDC as well as M1 and M2 macrophages upon treatment with various stimuli, especially upon viral infection. In line with this, a batch of SARS‐CoV‐2 produced in Mycoplasma ‐contaminated VeroE6 cells induced high levels of IL‐6 and TNF‐α while treatment with the non‐contaminated virus stock did not result in expression of cytokines. Our data indicate that Mycoplasma contamination has a major impact on the experimental outcome of infection experiments using human immune cells and therefore can result in misinterpretation of experimental data.
- Open Access
- 20 November 2025
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 9 (8) , 103256
Season-dependent low basal CD86 expression promotes immune cell activation upon treatment with plasma-derived factor Ⅷ products
- 20 November 2025
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 9 (8) , 103256
Open AccessSeason-dependent low basal CD86 expression promotes immune cell activation upon treatment with plasma-derived factor Ⅷ products
- Open Access
- 16 September 2025
- Published by Taylor & Francis in Emerging Microbes & Infections
- Vol. 14 (1) , 2556718
Influenza A virus-induced interferon-alpha production by myeloid dendritic cells and macrophages requires productive infection
Severe Influenza A virus (IAV) infections are accompanied by a cytokine storm with type I interferon (IFN) as the main driver. Besides epithelial cells, alveolar macrophages and infiltrating dendritic cells are target cells for IAV. IAV are classified into different strains, defined by their major surface glycoproteins hemagglutinin (HA) and neuraminidase (NA). So far, 19 HA subtypes and 11 NA subtypes are known. However, it is not well understood, why infection with certain IAV strains results in a cytokine storm with severe outcomes, while other IAV strains only cause mild infections.In order to address this question, we investigated six seasonal and five highly pathogenic avian IAV (HPAIV) strains using primary human ex vivo isolated plasmacytoid dendritic cells (pDC), as well as in vitro differentiated myeloid dendritic cells (mDC) and macrophages (type M1 and M2). Our data reveal that IFN-α production by mDC and macrophages but not by pDC is dependent on productive infection with the respective IAV strain. In contrast to IFN-α production in pDCs, IFN-α production by mDC as well as M1 and M2 macrophages is mainly induced by HPAIV strains, indicating that other immune cells apart from pDC might have an impact on induction of type I interferon as the main driver of the cytokine storm in the patients and the severity of the associated disease. Our findings may provide insights into the viral tropism and host response upon infection with different IAV strains and improve the understanding of the accompanied pathogenesis.
- 16 September 2025
- Published by Taylor & Francis in Emerging Microbes & Infections
- Vol. 14 (1) , 2556718
Open AccessInfluenza A virus-induced interferon-alpha production by myeloid dendritic cells and macrophages requires productive infection
Severe Influenza A virus (IAV) infections are accompanied by a cytokine storm with type I interferon (IFN) as the main driver. Besides epithelial cells, alveolar macrophages and infiltrating dendritic cells are target cells for IAV. IAV are classified into different strains, defined by their major surface glycoproteins hemagglutinin (HA) and neuraminidase (NA). So far, 19 HA subtypes and 11 NA subtypes are known. However, it is not well understood, why infection with certain IAV strains results in a cytokine storm with severe outcomes, while other IAV strains only cause mild infections.In order to address this question, we investigated six seasonal and five highly pathogenic avian IAV (HPAIV) strains using primary human ex vivo isolated plasmacytoid dendritic cells (pDC), as well as in vitro differentiated myeloid dendritic cells (mDC) and macrophages (type M1 and M2). Our data reveal that IFN-α production by mDC and macrophages but not by pDC is dependent on productive infection with the respective IAV strain. In contrast to IFN-α production in pDCs, IFN-α production by mDC as well as M1 and M2 macrophages is mainly induced by HPAIV strains, indicating that other immune cells apart from pDC might have an impact on induction of type I interferon as the main driver of the cytokine storm in the patients and the severity of the associated disease. Our findings may provide insights into the viral tropism and host response upon infection with different IAV strains and improve the understanding of the accompanied pathogenesis.
- Open Access
- 14 August 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (8) , e0329700
Immune cells play a critical role in cytokine- and endotoxin-mediated endothelial permeability
Vascular leakage (VL) is a severe pathology occurring in a broad range of scenarios, e.g., during sepsis, cytokine storms, or as side effect of immunotherapies. Its severity is underlined by the high lethality rate of 20−30% for the systemic capillary leakage syndrome. While many compounds are reported to affect endothelial cell (EC)-activation, exact mechanisms behind VL remain unclear. We analyzed activation, viability, cytokine secretion, and relative permeability of human umbilical vein endothelial cells (HUVECs) upon treatment with 16 different stimuli. Relative HUVEC-permeability was assessed in a trans-well-based leakage assay in presence or absence of human peripheral blood mononuclear cells (PBMCs). HUVEC-activation is characterized by correlating upregulation of intercellular adhesion molecule (ICAM)-1, vascular cell adhesion molecule (VCAM)-1, and E-selectin, as well as production of interleukin (IL)-8, monocyte chemoattractant protein (MCP)-1, and IL-6. Strong HUVEC-activation and reduced viability was observed upon treatment with IL-1β, tumor necrosis factor (TNF)-α, a TGN1412-induced cytokine cocktail (SNTGN1412), thrombin, and lipopolysaccharide (LPS). Only thrombin, SNTGN1412, and vascular endothelial growth factor (VEGF) led to increased relative permeability, while other compounds associated with vascular leakage, including TNF-α, IL-1β, or LPS, had no direct effect on relative HUVEC-permeability. Interestingly, co-cultures with PBMCs mediated IL-1β- and LPS- but not TNF-α-induced relative HUVEC-permeability. In our study, we show that HUVEC activation upon direct stimulation does not necessarily result in increased relative permeability or massive cytokine production. Interestingly, we could demonstrate that activated HUVECs respond with a conserved pattern of markers, independent from the stimulus used. Moreover, we observed that the interplay with immune cells is critical to enhance relative HUVEC-permeability, which however depended on the stimulus applied suggesting different mechanisms of immune-mediated VL. A better understanding of VL will uncover potential treatment-targets for patients suffering from VL and help to improve safety-assessment of leakage-associated immunotherapies.
- 14 August 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (8) , e0329700
Open AccessImmune cells play a critical role in cytokine- and endotoxin-mediated endothelial permeability
Vascular leakage (VL) is a severe pathology occurring in a broad range of scenarios, e.g., during sepsis, cytokine storms, or as side effect of immunotherapies. Its severity is underlined by the high lethality rate of 20−30% for the systemic capillary leakage syndrome. While many compounds are reported to affect endothelial cell (EC)-activation, exact mechanisms behind VL remain unclear. We analyzed activation, viability, cytokine secretion, and relative permeability of human umbilical vein endothelial cells (HUVECs) upon treatment with 16 different stimuli. Relative HUVEC-permeability was assessed in a trans-well-based leakage assay in presence or absence of human peripheral blood mononuclear cells (PBMCs). HUVEC-activation is characterized by correlating upregulation of intercellular adhesion molecule (ICAM)-1, vascular cell adhesion molecule (VCAM)-1, and E-selectin, as well as production of interleukin (IL)-8, monocyte chemoattractant protein (MCP)-1, and IL-6. Strong HUVEC-activation and reduced viability was observed upon treatment with IL-1β, tumor necrosis factor (TNF)-α, a TGN1412-induced cytokine cocktail (SNTGN1412), thrombin, and lipopolysaccharide (LPS). Only thrombin, SNTGN1412, and vascular endothelial growth factor (VEGF) led to increased relative permeability, while other compounds associated with vascular leakage, including TNF-α, IL-1β, or LPS, had no direct effect on relative HUVEC-permeability. Interestingly, co-cultures with PBMCs mediated IL-1β- and LPS- but not TNF-α-induced relative HUVEC-permeability. In our study, we show that HUVEC activation upon direct stimulation does not necessarily result in increased relative permeability or massive cytokine production. Interestingly, we could demonstrate that activated HUVECs respond with a conserved pattern of markers, independent from the stimulus used. Moreover, we observed that the interplay with immune cells is critical to enhance relative HUVEC-permeability, which however depended on the stimulus applied suggesting different mechanisms of immune-mediated VL. A better understanding of VL will uncover potential treatment-targets for patients suffering from VL and help to improve safety-assessment of leakage-associated immunotherapies.
- Open Access
- 9 December 2024
- Published by Taylor & Francis in Journal of Immunotoxicology
- Vol. 21 (sup1) , S5-S12
Using interactive platforms to encode, manage and explore immune-related adverse outcome pathways
This work focuses on the need for modeling and predicting adverse outcomes in immunotoxicology to improve nonclinical assessments of the safety of immunomodulatory therapies. The integrated approach includes, first, the adverse outcome pathway concept established in the toxicology field, and, second, the systems medicine disease map approach for describing molecular mechanisms involved in a particular pathology. The proposed systems immunotoxicology workflow is illustrated with chimeric antigen receptor (CAR) T cell treatment as a use case. To this end, the linear adverse outcome pathway (AOP) is expanded into a molecular interaction model in standard systems biology formats. Then it is shown how knowledge related to immunotoxic events can be integrated, encoded, managed, and explored to benefit the research community. The map is accessible online at https://imsavar.elixir-luxembourg.org via the MINERVA Platform for browsing, commenting, and data visualization. Our work transforms a graphical illustration of an AOP into a digitally structured and standardized form, featuring precise and controlled vocabulary and supporting reproducible computational analyses. Because of annotations to source literature and databases, the map can be further expanded to match the evolving knowledge and research questions.
- 9 December 2024
- Published by Taylor & Francis in Journal of Immunotoxicology
- Vol. 21 (sup1) , S5-S12
Open AccessUsing interactive platforms to encode, manage and explore immune-related adverse outcome pathways
This work focuses on the need for modeling and predicting adverse outcomes in immunotoxicology to improve nonclinical assessments of the safety of immunomodulatory therapies. The integrated approach includes, first, the adverse outcome pathway concept established in the toxicology field, and, second, the systems medicine disease map approach for describing molecular mechanisms involved in a particular pathology. The proposed systems immunotoxicology workflow is illustrated with chimeric antigen receptor (CAR) T cell treatment as a use case. To this end, the linear adverse outcome pathway (AOP) is expanded into a molecular interaction model in standard systems biology formats. Then it is shown how knowledge related to immunotoxic events can be integrated, encoded, managed, and explored to benefit the research community. The map is accessible online at https://imsavar.elixir-luxembourg.org via the MINERVA Platform for browsing, commenting, and data visualization. Our work transforms a graphical illustration of an AOP into a digitally structured and standardized form, featuring precise and controlled vocabulary and supporting reproducible computational analyses. Because of annotations to source literature and databases, the map can be further expanded to match the evolving knowledge and research questions.
- Open Access
- 9 December 2024
- Published by Taylor & Francis in Journal of Immunotoxicology
- Vol. 21 (sup1) , S79-S88
Analyzing IL-2-induced vascular leakage with an irAOP as tool
Immune-related adverse outcome pathways (irAOPs) are a toxicological tool for the structuring of complex immunological mechanisms. The EU-funded IMI-project imSAVAR analyses the applicability of irAOPs in pre-clinical safety assessment of immunotherapies. Here, we use immunotherapy with interleukin (IL)-2 as a use case to develop an irAOP for IL-2-mediated vascular leakage (VL). Despite severe side effects observed upon high-dose treatment, IL-2 remains a promising candidate for cancer- and autoimmune therapy. The secondary systemic capillary leakage syndrome is described by a high mortality and a lethality rate of 20 - 30%. However, due to its non-specific symptoms, it remains a serious but under-diagnosed pathology. VL as general phenomenon is associated with several pro-inflammatory scenarios or observed as severe side effect of immunotherapies. In such situations, the physiological condition, in which endothelial cells (ECs) form the semipermeable seal of the vasculature, can escalate into pathological vascular permeability and finally VL. Although EC-biology and mechanisms underlying VL are ongoing subjects of research since many years, exact understanding of VL pathophysiology remains unclear. With this review, we provide an overview of the development of VL from an immunological perspective in the context of high-dose IL-2 immunotherapy. We structured the corresponding knowledge and generated an irAOP for IL-2-mediated VL with the aim to identify gaps and possible biomarkers. Gained insights from this theoretical approach facilitate the identification of relevant scientific questions as a basis for concrete experimental work. Integration of novel experiment-based knowledge into the existing irAOP could close a 'feedback-loop' by enabling irAOP-refinement and the identification of new questions. At the same time this could give rise to important information to improve test systems for IL-2-based immunotherapy safety-assessment and overall the approach to understand, prevent, or predict VL as critical side effect of other clinical conditions.
- 9 December 2024
- Published by Taylor & Francis in Journal of Immunotoxicology
- Vol. 21 (sup1) , S79-S88
Open AccessAnalyzing IL-2-induced vascular leakage with an irAOP as tool
Immune-related adverse outcome pathways (irAOPs) are a toxicological tool for the structuring of complex immunological mechanisms. The EU-funded IMI-project imSAVAR analyses the applicability of irAOPs in pre-clinical safety assessment of immunotherapies. Here, we use immunotherapy with interleukin (IL)-2 as a use case to develop an irAOP for IL-2-mediated vascular leakage (VL). Despite severe side effects observed upon high-dose treatment, IL-2 remains a promising candidate for cancer- and autoimmune therapy. The secondary systemic capillary leakage syndrome is described by a high mortality and a lethality rate of 20 - 30%. However, due to its non-specific symptoms, it remains a serious but under-diagnosed pathology. VL as general phenomenon is associated with several pro-inflammatory scenarios or observed as severe side effect of immunotherapies. In such situations, the physiological condition, in which endothelial cells (ECs) form the semipermeable seal of the vasculature, can escalate into pathological vascular permeability and finally VL. Although EC-biology and mechanisms underlying VL are ongoing subjects of research since many years, exact understanding of VL pathophysiology remains unclear. With this review, we provide an overview of the development of VL from an immunological perspective in the context of high-dose IL-2 immunotherapy. We structured the corresponding knowledge and generated an irAOP for IL-2-mediated VL with the aim to identify gaps and possible biomarkers. Gained insights from this theoretical approach facilitate the identification of relevant scientific questions as a basis for concrete experimental work. Integration of novel experiment-based knowledge into the existing irAOP could close a 'feedback-loop' by enabling irAOP-refinement and the identification of new questions. At the same time this could give rise to important information to improve test systems for IL-2-based immunotherapy safety-assessment and overall the approach to understand, prevent, or predict VL as critical side effect of other clinical conditions.
- Open Access
- 9 December 2024
- Published by Taylor & Francis in Journal of Immunotoxicology
- Vol. 21 (sup1) , S38-S47
Revival of recombinant IL-2 therapy – approaches from the past until today
Interleukin-2 (IL-2) was one of the first cytokines discovered and its central role in T cell function soon led to the notion that the cytokine could specifically activate immune cells to combat cancer cells. Recombinant human IL-2 (recIL-2) belonged to the first anti-cancer immunotherapeutics that received marketing authorization and while it mediated anti-tumor effects in some cancer entities, treatment was associated with severe and systemic side effects. RecIL-2 holds an exceptional therapeutic potential, which can either lead to stimulation of the immune system - favorable during cancer treatment - or immunosuppression - used for treatment of inflammatory diseases such as autoimmunity. Due to these pleiotropic immune effects, recIL-2 therapy is still a hot topic in research and modified recIL-2 drug candidates show ameliorated efficacy and safety in pre-clinical and clinical studies. The Immune Safety Avatar (imSAVAR) consortium aims to systemically assess mechanisms leading to adverse events provoked by recIL-2 immunotherapy as a use case in order to aid safety evaluation of future recIL-2-based therapies. Here, we summarize the historical use of recIL-2 therapy, associated side effects, and describe the molecular basis of the dual role of IL-2. Finally, an overview of new recIL-2 compounds and delivery systems, which are currently being developed, will be given, highlighting a possible comeback of recIL-2 therapy.
- 9 December 2024
- Published by Taylor & Francis in Journal of Immunotoxicology
- Vol. 21 (sup1) , S38-S47
Open AccessRevival of recombinant IL-2 therapy – approaches from the past until today
Interleukin-2 (IL-2) was one of the first cytokines discovered and its central role in T cell function soon led to the notion that the cytokine could specifically activate immune cells to combat cancer cells. Recombinant human IL-2 (recIL-2) belonged to the first anti-cancer immunotherapeutics that received marketing authorization and while it mediated anti-tumor effects in some cancer entities, treatment was associated with severe and systemic side effects. RecIL-2 holds an exceptional therapeutic potential, which can either lead to stimulation of the immune system - favorable during cancer treatment - or immunosuppression - used for treatment of inflammatory diseases such as autoimmunity. Due to these pleiotropic immune effects, recIL-2 therapy is still a hot topic in research and modified recIL-2 drug candidates show ameliorated efficacy and safety in pre-clinical and clinical studies. The Immune Safety Avatar (imSAVAR) consortium aims to systemically assess mechanisms leading to adverse events provoked by recIL-2 immunotherapy as a use case in order to aid safety evaluation of future recIL-2-based therapies. Here, we summarize the historical use of recIL-2 therapy, associated side effects, and describe the molecular basis of the dual role of IL-2. Finally, an overview of new recIL-2 compounds and delivery systems, which are currently being developed, will be given, highlighting a possible comeback of recIL-2 therapy.
- Open Access
- 1 September 2023
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1194733
Interleukin-36γ is causative for liver damage upon infection with Rift Valley fever virus in type I interferon receptor-deficient mice
Type I interferons (IFN) are pro-inflammatory cytokines which can also exert anti-inflammatory effects via the regulation of interleukin (IL)-1 family members. Several studies showed that interferon receptor (IFNAR)-deficient mice develop severe liver damage upon treatment with artificial agonists such as acetaminophen or polyinosinic:polycytidylic acid. In order to investigate if these mechanisms also play a role in an acute viral infection, experiments with the Bunyaviridae family member Rift Valley fever virus (RVFV) were performed. Upon RVFV clone (cl)13 infection, IFNAR-deficient mice develop a severe liver injury as indicated by high activity of serum alanine aminotransferase (ALT) and histological analyses. Infected IFNAR-/- mice expressed high amounts of IL-36γ within the liver, which was not observed in infected wildtype (WT) animals. In line with this, treatment of WT mice with recombinant IL-36γ induced ALT activity. Furthermore, administration of an IL-36 receptor antagonist prior to infection prevented the formation of liver injury in IFNAR-/- mice, indicating that IL-36γ is causative for the observed liver damage. Mice deficient for adaptor molecules of certain pattern recognition receptors indicated that IL-36γ induction was dependent on mitochondrial antiviral-signaling protein and the retinoic acid-inducible gene-I-like receptor. Consequently, cell type-specific IFNAR knockouts revealed that type I IFN signaling in myeloid cells is critical in order to prevent IL-36γ expression and liver injury upon viral infection. Our data demonstrate an anti-inflammatory role of type I IFN in a model for virus-induced hepatitis by preventing the expression of the novel IL-1 family member IL-36γ.
- 1 September 2023
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1194733
Open AccessInterleukin-36γ is causative for liver damage upon infection with Rift Valley fever virus in type I interferon receptor-deficient mice
Type I interferons (IFN) are pro-inflammatory cytokines which can also exert anti-inflammatory effects via the regulation of interleukin (IL)-1 family members. Several studies showed that interferon receptor (IFNAR)-deficient mice develop severe liver damage upon treatment with artificial agonists such as acetaminophen or polyinosinic:polycytidylic acid. In order to investigate if these mechanisms also play a role in an acute viral infection, experiments with the Bunyaviridae family member Rift Valley fever virus (RVFV) were performed. Upon RVFV clone (cl)13 infection, IFNAR-deficient mice develop a severe liver injury as indicated by high activity of serum alanine aminotransferase (ALT) and histological analyses. Infected IFNAR-/- mice expressed high amounts of IL-36γ within the liver, which was not observed in infected wildtype (WT) animals. In line with this, treatment of WT mice with recombinant IL-36γ induced ALT activity. Furthermore, administration of an IL-36 receptor antagonist prior to infection prevented the formation of liver injury in IFNAR-/- mice, indicating that IL-36γ is causative for the observed liver damage. Mice deficient for adaptor molecules of certain pattern recognition receptors indicated that IL-36γ induction was dependent on mitochondrial antiviral-signaling protein and the retinoic acid-inducible gene-I-like receptor. Consequently, cell type-specific IFNAR knockouts revealed that type I IFN signaling in myeloid cells is critical in order to prevent IL-36γ expression and liver injury upon viral infection. Our data demonstrate an anti-inflammatory role of type I IFN in a model for virus-induced hepatitis by preventing the expression of the novel IL-1 family member IL-36γ.
- Open Access
Using interactive platforms to encode, manage and explore immune-related adverse outcome pathways
We address the need for modelling and predicting adverse outcomes in immunotoxicology to improve non-clinical assessments of immunomodulatory therapy safety and efficacy. The integrated approach includes, first, the adverse outcome pathway concept established in the toxicology field, and, second, the systems medicine disease map approach for describing molecular mechanisms involved in a particular pathology. The proposed systems immunotoxicology workflow is demonstrated with CAR T cell treatment as a use case. To this end, the linear adverse outcome pathway (AOP) is expanded into a molecular interaction model in standard systems biology formats. Then it is shown how knowledge related to immunotoxic events can be integrated, encoded, managed and explored to benefit the research community. The map is accessible online via the MINERVA Platform for browsing, commenting and data visualisation (https://minerva.pages.uni.lu). Our work transforms a graphical illustration of an AOP into a digitally structured and standardised form, featuring precise and controlled vocabulary and supporting reproducible computational analyses. Because of annotations to source literature and databases, the map can be further expanded to match the evolving knowledge and research questions.
Open AccessUsing interactive platforms to encode, manage and explore immune-related adverse outcome pathways
We address the need for modelling and predicting adverse outcomes in immunotoxicology to improve non-clinical assessments of immunomodulatory therapy safety and efficacy. The integrated approach includes, first, the adverse outcome pathway concept established in the toxicology field, and, second, the systems medicine disease map approach for describing molecular mechanisms involved in a particular pathology. The proposed systems immunotoxicology workflow is demonstrated with CAR T cell treatment as a use case. To this end, the linear adverse outcome pathway (AOP) is expanded into a molecular interaction model in standard systems biology formats. Then it is shown how knowledge related to immunotoxic events can be integrated, encoded, managed and explored to benefit the research community. The map is accessible online via the MINERVA Platform for browsing, commenting and data visualisation (https://minerva.pages.uni.lu). Our work transforms a graphical illustration of an AOP into a digitally structured and standardised form, featuring precise and controlled vocabulary and supporting reproducible computational analyses. Because of annotations to source literature and databases, the map can be further expanded to match the evolving knowledge and research questions.
- Open Access
- 2 February 2023
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 108 (6) , 1579-1589
Complement protein C3a enhances adaptive immune responses towards FVIII products
The most serious complication in the treatment of hemophilia A (HA) is the development of factor (F)VIII inhibitors or antidrug antibodies (ADA) occurring in 25-35% of patients with severe HA. The immunological mechanisms underlying the development of ADA against FVIII products have not been completely understood yet. Immunological danger signals associated with events such as infection or surgery have been suggested to play a critical role. In previous studies, we demonstrated that plasma-derived (pd)FVIII but not recombinant (r)FVIII can activate human monocyte-derived dendritic cells (DC) in a danger signal-dependent manner, which subsequently mediate the proliferation of autologous CD4+ T cells. In this study, we investigated the ability of plasma components, naturally present in pdFVIII products, to mediate T-cell responses. In fact, we show that addition of plasma to rFVIII plus lipopolysaccharide (LPS)-stimulated DC induces proliferation of autologous CD4+ T cells. Interestingly, although DC pulsed with LPS plus plasma induce T-cell proliferation upon co-culture, the addition of FVIII significantly increases the number of proliferating as well as FVIII-specific CD4+ T cells. Total proliferating CD4+ T cells and FVIII-specific subsets were identified mainly as central memory T cells. Experiments using blocking antibodies and receptor antagonists revealed that the complement proteins C3a and, to a lesser extent, C5a are critically involved in these LPS-mediated T-cell responses. Collectively, our results indicate that complement proteins are potent drivers of T-cell responses to FVIII. Data presented provide a model how event-related substitution of FVIII in HA patients might contribute to inhibitor development.
- 2 February 2023
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 108 (6) , 1579-1589
Open AccessComplement protein C3a enhances adaptive immune responses towards FVIII products
The most serious complication in the treatment of hemophilia A (HA) is the development of factor (F)VIII inhibitors or antidrug antibodies (ADA) occurring in 25-35% of patients with severe HA. The immunological mechanisms underlying the development of ADA against FVIII products have not been completely understood yet. Immunological danger signals associated with events such as infection or surgery have been suggested to play a critical role. In previous studies, we demonstrated that plasma-derived (pd)FVIII but not recombinant (r)FVIII can activate human monocyte-derived dendritic cells (DC) in a danger signal-dependent manner, which subsequently mediate the proliferation of autologous CD4+ T cells. In this study, we investigated the ability of plasma components, naturally present in pdFVIII products, to mediate T-cell responses. In fact, we show that addition of plasma to rFVIII plus lipopolysaccharide (LPS)-stimulated DC induces proliferation of autologous CD4+ T cells. Interestingly, although DC pulsed with LPS plus plasma induce T-cell proliferation upon co-culture, the addition of FVIII significantly increases the number of proliferating as well as FVIII-specific CD4+ T cells. Total proliferating CD4+ T cells and FVIII-specific subsets were identified mainly as central memory T cells. Experiments using blocking antibodies and receptor antagonists revealed that the complement proteins C3a and, to a lesser extent, C5a are critically involved in these LPS-mediated T-cell responses. Collectively, our results indicate that complement proteins are potent drivers of T-cell responses to FVIII. Data presented provide a model how event-related substitution of FVIII in HA patients might contribute to inhibitor development.